Contents
Utah is home to many world-class clinical research facilities, like the Highland Clinical Research and Granger Medical Research. The state is known for its exceptional healthcare infrastructure and highest standard of care.
We partnered up with research institutions and medical experts to bring you the latest and most promising clinical trials near you.
Clinical Trials For Disease Areas in Utah
Clinical research trials in Utah boast a diverse landscape of research strengths across different disease areas. Experts excel in the fields of oncology, cardiology, pediatrics, neurology, rheumatology, and autoimmune disorders.
For example, the Utah Innovation Center brought attention to Kuda Therapeutics’ success story. The company is working to create new treatments for kidney cancer. Their main goal is to turn exciting scientific discoveries into powerful cancer drugs.
You too can become a vital part of medical progress. Browse the list below, and discover active and future clinical trials in your area.
Follow-up Visit of High Risk Infants
Recruiting
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may... Read More
The NICHD Neonatal Research Network's Follow-Up study is a multi-center cohort in which surviving extremely low birth-weight infants born in participating network centers receive neurodevelopmental, neurosensory and functional assessments at 22-26 months corrected age (Infants born prior to July 1, 2012 were seen at 18-22 months corrected age). Data regarding pregnancy and neonatal outcome are collected prospectively. The goal is to identify potential maternal and neonatal risk factors that may affect infant neurodevelopment. Read Less
Gender:
ALL
Ages:
Between 18 months and 26 months
Trial Updated:
02/11/2025
Locations: University of Utah, Salt Lake City, Utah
University of Utah, Salt Lake City, Utah
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
A Prospective Database of Infants With Cholestasis
Recruiting
Biliary atresia, idiopathic neonatal hepatitis, and specific genetic cholestatic conditions are the most common causes of jaundice and hyperbilirubinemia that continue beyond the newborn period. The long term goal of the Childhood Liver Disease Research Network (ChiLDReN) is to establish a database of clinical information and plasma, serum, and tissue samples from cholestatic children to facilitate research and to perform clinical, epidemiological and therapeutic trials in these important pediat... Read More
Biliary atresia, idiopathic neonatal hepatitis, and specific genetic cholestatic conditions are the most common causes of jaundice and hyperbilirubinemia that continue beyond the newborn period. The long term goal of the Childhood Liver Disease Research Network (ChiLDReN) is to establish a database of clinical information and plasma, serum, and tissue samples from cholestatic children to facilitate research and to perform clinical, epidemiological and therapeutic trials in these important pediatric liver diseases. Read Less
Gender:
ALL
Ages:
6 months and below
Trial Updated:
05/19/2025
Locations: University of Utah, Salt Lake City, Utah
University of Utah, Salt Lake City, Utah
Conditions: Biliary Atresia, Neonatal Cholestasis
Generic Database of Very Low Birth Weight Infants
Recruiting
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials.
The Generic Database (GDB) is a registry of very low birth weight infants born alive in NICHD Neonatal Research Network (NRN) centers. The GDB collects observational baseline data on both mothers and infants, and the therapies used and outcomes of the infants. The information collected is not specific to a disease or treatment (i.e., it is "generic"). Data are analyzed to find associations and trends between baseline information, treatments, and infant outcome, and to develop future NRN trials. Read Less
Gender:
ALL
Ages:
14 days and below
Trial Updated:
02/11/2025
Locations: University of Utah, Salt Lake City, Utah
University of Utah, Salt Lake City, Utah
Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
Mucopolysaccharidosis I (MPS I) Registry
Recruiting
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities.
The objectives of the Registry are:
* To evaluate the lon... Read More
The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients receiving enzyme replacement therapy, such as Aldurazyme (Recombinant Human Alpha-L-Iduronidase), or other treatment modalities.
The objectives of the Registry are:
* To evaluate the long-term effectiveness and safety of Aldurazyme® (laronidase)
* To characterize and describe the MPS I population as a whole, including the variability, progression, and natural history of MPS I
* To help the MPS I medical community with the development of recommendations for monitoring patients and reports on patient outcomes to optimize patient care Read Less
Gender:
ALL
Ages:
All
Trial Updated:
11/19/2024
Locations: University of Utah Health Hospital- Site Number : 840092, Salt Lake City, Utah
University of Utah Health Hospital- Site Number : 840092, Salt Lake City, Utah
Conditions: Mucopolysaccharidosis I (MPS I)
The Genetics of Polycystic Ovarian Syndrome
Recruiting
The goal of this study is to determine the genetic basis of polycystic ovary syndrome (PCOS). We will first look for genes in the Icelandic population, where large family trees are known and it is easier to search for genes. We will then determine whether these same genes are important in U.S. PCOS patients.
The goal of this study is to determine the genetic basis of polycystic ovary syndrome (PCOS). We will first look for genes in the Icelandic population, where large family trees are known and it is easier to search for genes. We will then determine whether these same genes are important in U.S. PCOS patients. Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/01/2020
Locations: University of Utah, Salt Lake City, Utah
University of Utah, Salt Lake City, Utah
Conditions: Polycystic Ovary Syndrome
Fabry Disease Registry & Pregnancy Sub-registry
Recruiting
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The primary objectives of the Registry are:
* To enhance the understanding of the variability, progression, and natural history of F... Read More
The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician.
The primary objectives of the Registry are:
* To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease;
* To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care;
* To characterize and describe the Fabry population as a whole;
* To evaluate the long-term safety and effectiveness of Fabrazyme®
Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Fabry Registry, regardless of whether she is receiving disease-specific therapy (such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global regulatory requirements, to support product development/reimbursement, and for other research and non-research-related purposes. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician. If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/07/2025
Locations: University of Utah Department of Medical Genetics- Site Number : 840043, Salt Lake City, Utah
University of Utah Department of Medical Genetics- Site Number : 840043, Salt Lake City, Utah
Conditions: Fabry Disease
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)
Recruiting
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications... Read More
The PROMISSE Study is an observational study of 700 pregnant patients, enrolled at nine major clinical centers. The purpose of the study is 1) to determine whether certain proteins (called complement split products) that can injure healthy organs can be used to predict poor pregnancy outcome in patients with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS), and/or 2) to determine whether elevated levels of circulating antiangiogenic factors predict pregnancy complications in patients with aPL antibodies and/or SLE. Read Less
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
04/09/2025
Locations: University of Utah Salt Lake City, Salt Lake City, Utah
University of Utah Salt Lake City, Salt Lake City, Utah
Conditions: Systemic Lupus Erythematosus, Antiphospholipid Syndrome
Pompe Disease Registry Protocol
Recruiting
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes.
The objectives of the Registry are:
* To enhance understanding of t... Read More
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both treated and not. Data from the Registry are also used to fulfill various global regulatory commitments, to support product development/reimbursement, and for other research and non-research related purposes.
The objectives of the Registry are:
* To enhance understanding of the variability, progression, identification, and natural history of Pompe disease, with the ultimate goal of better guiding and assessing therapeutic intervention.
* To assist the Pompe medical community with the development of recommendations for monitoring patients, and to provide reports on patient outcomes, to optimize patient care.
* To characterize the Pompe disease population.
* To evaluate the long-term effectiveness of alglucosidase alfa. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
08/06/2025
Locations: University of Utah Department of Medical Genetics- Site Number : 840043, Salt Lake City, Utah
University of Utah Department of Medical Genetics- Site Number : 840043, Salt Lake City, Utah
Conditions: Glycogen Storage Disease Type II, Pompe Disease
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
Recruiting
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this... Read More
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA. Read Less
Gender:
ALL
Ages:
All
Trial Updated:
05/15/2025
Locations: University of Utah, Salt Lake City, Utah
University of Utah, Salt Lake City, Utah
Conditions: Eosinophilic Granulomatosis With Polyangiitis, Churg-Strauss Syndrome
Biliary Atresia Study in Infants and Children
Recruiting
Little is known about the factors that cause biliary atresia nor the factors that influence disease progression. The purpose of this study is to collect the pertinent clinical information, genetic material and body fluid samples to enable investigators to address the following aims: To identify the gene or genes implicated in the etiology of BA; To identify polymorphisms that may be important in disease progression such as HLA polymorphisms; To characterize the natural history of the older, non-... Read More
Little is known about the factors that cause biliary atresia nor the factors that influence disease progression. The purpose of this study is to collect the pertinent clinical information, genetic material and body fluid samples to enable investigators to address the following aims: To identify the gene or genes implicated in the etiology of BA; To identify polymorphisms that may be important in disease progression such as HLA polymorphisms; To characterize the natural history of the older, non-transplanted child with BA. Read Less
Gender:
ALL
Ages:
Between 6 months and 20 years
Trial Updated:
05/19/2025
Locations: University of Utah, Salt Lake City, Utah
University of Utah, Salt Lake City, Utah
Conditions: Biliary Atresia
Paid Clinical Trials in Utah
Test drugs, get paid. Every volunteer can receive compensation for their effort, time, and expenses associated with paid clinical trials in Utah. That’s because many people can’t afford to take time off from work. This makes financial compensation a valuable addition to any trial.
With UT paid clinical trials, you can get anywhere from $1,000 to $10,000. The higher the risks and the longer the trial, the better the pay.
Clinical Trials For Health Volunteers in Utah
Health volunteers are an integral part of clinical trials. Both those in good health and with a specific disease can help advance medicine. Research teams in Utah constantly need more volunteers. That’s because, without your help, research studies wouldn’t be possible.
Check the trials below to find out more.
A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception
Recruiting
This is a Phase I multicenter, open-label, dose-ranging, three-dose PK and PD study of injectable LB administered as an IM or SQ injection at 40 mg, and subsequently at 50mg SQ and then 60 mg SQ depending on the preliminary pharmacokinetic and pharmacodynamic results obtained with 40 mg dosing.
This is a Phase I multicenter, open-label, dose-ranging, three-dose PK and PD study of injectable LB administered as an IM or SQ injection at 40 mg, and subsequently at 50mg SQ and then 60 mg SQ depending on the preliminary pharmacokinetic and pharmacodynamic results obtained with 40 mg dosing. Read Less
Gender:
FEMALE
Ages:
Between 18 years and 40 years
Trial Updated:
08/11/2023
Locations: University of Utah, Salt Lake City, Utah
University of Utah, Salt Lake City, Utah
Conditions: Healthy Women, Female Contraception
Single and Multiple Ascending Dose Study and Food Effect Study for AG181
Recruiting
The primary purpose of this study is to assess the safety and tolerability of AG-181 in healthy participants after oral administration of single ascending dose (SAD) of AG-181 in Part 1 and multiple ascending dose (MAD) in Part 2 along with the effect of food on the pharmacokinetics (PK) of single oral doses of AG-181 in healthy participants in Part 3.
The primary purpose of this study is to assess the safety and tolerability of AG-181 in healthy participants after oral administration of single ascending dose (SAD) of AG-181 in Part 1 and multiple ascending dose (MAD) in Part 2 along with the effect of food on the pharmacokinetics (PK) of single oral doses of AG-181 in healthy participants in Part 3. Read Less
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/18/2025
Locations: ICON 1255 East 3900 South, Salt Lake City, Utah
ICON 1255 East 3900 South, Salt Lake City, Utah
Conditions: Healthy Volunteers
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy Participants
Recruiting
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of high dose of BMS-986278 in healthy participants and to assess the effect of BMS-986278 on the ECG intervals in healthy participants.
The purpose of this study is to determine the safety, tolerability, and pharmacokinetics (PK) of high dose of BMS-986278 in healthy participants and to assess the effect of BMS-986278 on the ECG intervals in healthy participants. Read Less
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/17/2025
Locations: ICON Salt Lake City, Salt Lake City, Utah
ICON Salt Lake City, Salt Lake City, Utah
Conditions: Healthy Volunteers
Natural Product System and Lifestyle Modification
Recruiting
The goal of this clinical trial is to learn whether four dietary supplements and lifestyle changes can affect gene expression and blood markers in healthy volunteers. The main questions it aims to answer are:
1. How does daily ingestion of dietary supplements affect gene expression and hsCRP and vitamin D levels measured in blood?
2. How does daily ingestion of dietary supplements affect anthropometric measurements, sleep and physical activity, and gut microbiome composition?
3. How does daily... Read More
The goal of this clinical trial is to learn whether four dietary supplements and lifestyle changes can affect gene expression and blood markers in healthy volunteers. The main questions it aims to answer are:
1. How does daily ingestion of dietary supplements affect gene expression and hsCRP and vitamin D levels measured in blood?
2. How does daily ingestion of dietary supplements affect anthropometric measurements, sleep and physical activity, and gut microbiome composition?
3. How does daily ingestion of dietary supplements affect cognitive and subjective health parameters?
4. Do prescriptive lifestyle modifications affect the supplements' efficacy?
5. Is there a difference in outcomes between participants who take all four study supplements and those who take three study supplements with a placebo?
6. Is ingesting dietary supplements for 12 weeks safe, as measured by laboratory tests and adverse events? Read Less
Gender:
ALL
Ages:
Between 30 years and 55 years
Trial Updated:
04/29/2025
Locations: doTERRA International, Pleasant Grove, Utah
doTERRA International, Pleasant Grove, Utah
Conditions: Healthy
A Study to Assess Zilucoplan Concentration in Breast Milk of Healthy Lactating Women
Recruiting
The purpose of this study is to assess the steady state (SS) concentrations of zilucoplan (ZLP) and its major metabolites in mature breast milk of healthy study participants following injection of repeated once-daily doses of ZLP.
The purpose of this study is to assess the steady state (SS) concentrations of zilucoplan (ZLP) and its major metabolites in mature breast milk of healthy study participants following injection of repeated once-daily doses of ZLP. Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/30/2025
Locations: UP0137 1, Salt Lake City, Utah
UP0137 1, Salt Lake City, Utah
Conditions: Healthy Participants
A Study of LY4088044 in Healthy Participants
Recruiting
The purpose of this study is to evaluate how well LY4088044 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4088044 gets into the bloodstream and how long it takes the body to eliminate it.
The study will last up to approximately 92 weeks for Parts A, B, and C, excluding screening.
The purpose of this study is to evaluate how well LY4088044 is tolerated and what side effects may occur in healthy participants. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm). Blood tests will be performed to check how much LY4088044 gets into the bloodstream and how long it takes the body to eliminate it.
The study will last up to approximately 92 weeks for Parts A, B, and C, excluding screening. Read Less
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/01/2025
Locations: ICON, Salt Lake City, Utah
ICON, Salt Lake City, Utah
Conditions: Healthy
Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants
Recruiting
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults.
The purpose of this study is to investigate the safety, tolerability, and pharmacokinetics (PK) of single- and multiple-dose administration of S-892216-LAI in healthy adults. Read Less
Gender:
MALE
Ages:
Between 18 years and 55 years
Trial Updated:
08/12/2025
Locations: ICON Clinical Research: Salt Lake City, Salt Lake City, Utah
ICON Clinical Research: Salt Lake City, Salt Lake City, Utah
Conditions: Healthy Participants
Medical Discoveries and Innovation in Utah
Utah has made remarkable contributions to the field of medicine. The state has many monumental achievements. Here is a list of some of the most instrumental advancements, which were made possible thanks to studies and clinical trials.
- Gene therapy – Utah clinical research has played a pivotal role in the development of gene therapy techniques. Especially in the treatment of genetic disorders. The Intermountain Primary Children’s Hospital was one of the first in the U.S. to provide the gene therapy Zolgensma to toddlers. The therapy is designed to treat spinal muscular atrophy (SMA).
- Precision medicine research: The state of Utah has made significant strides in personalized medicine. Scientists have conducted many clinical trials for tailoring treatments based on the patient’s genetic makeup.
- 3D printing in medicine: The Center for Medical Innovation (CMI) is the first at the University of Utah to provide superior 3D printing tech. Unlike traditional methods that use filament or raisin, the Fuse 1 3D printer uses powder to craft parts for prototypes and final products.
Why Utah Is A Great Place For Clinical Research
For clinical research in Utah to succeed, volunteers from different ethnicities and races are always welcome. Based on recent data, the UT population is relatively diverse. About 77.2% of its residents are White, 14.8% are Hispanic, 2.5% are Asian, 2.3% are Multiracial, 1.2% are Black, 1.1% are Native Hawaiian, and 0.9% are American Indian.